Global and USA Cancer Immunotherapy Market Eyes on Revenue Excess of $80 billion, Finds New Report

The new report named Global & USA Cancer Immunotherapy Market Analysis to 2020” reveals that the cancer immunotherapy space will bea significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers’ Yervoy drug for melanoma (2011) and Dendreon’sProvenge(2010) for prostate cancer. Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb’s Yervoy, for example has earned revenues of about $960 million in 2013 and it is expected to have a market value of $1,775.2 million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $2.9 billion and $4.3 billion respectively in 2019.

“An unmet need in the cancer therapy market has paved the way for immunotherapies and has increased patient survival rates significantly” indicates research analyst of this report, “Today significant therapeutic interest into ADC’s, checkpoint inhibitors, cancer vaccines and anti-PD-1/PD-L1 agents are taking the market by storm, and we forecast vertical growth in this area within the next decade’. Therefore, it is no wonder that in 2013, most science journals hailed cancer immunotherapy as the breakthrough treatment of the year.

The interest on ADCs can be seen with the recent approvals of Adcetris (brentuximabvedotin) and Kadcyla (ado-trastuzumab emtansine). Currently, More than 15 companies are developing 30 different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and increasing pressure from patent expirations, big pharmaco’ recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The global market for cancer vaccines was worth about $4.4 billion and it is likely to reach $8.4 billion in 2020.

Immunotherapy is a proven powerful tool, either as a monotherapy or as a combination therapy with chemotherapy or radiation. For patients with metastatic skin cancer or kidney cancer, immunotherapy has been found to be more effective than the conventional options, with the possibility of even a complete cure. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 11 chapters supported by 114 tables and 41 figures, over 256 pages.

• An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies.
• Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
• Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
• Descriptions of  23 cancer immunotherapeutics approved and used as targeted drugs
• Insight into the various immunotherapeutics available for specific cancer types.
• Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
• Overall global cancer therapeutics market, leading market players and bestselling cancer drugs.
• Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
• Profiles, marketed products and products in pipeline of 76 companies that are mainly located in the U.S. and Europe.
• Summary table to identify the category of immunotherapy drug offered by the 76 companies.

Key Questions Answered in this Report

• What are the types of cancer immunotherapies?
• What are the immunotherapies approved between 1986 and 2014?
• What are the monoclonal antibodies (MAbs) approved by FDA to treat different types of cancers?
• What are naked MAbs and how many of them have been approved by FDA?
• What are antibody-drug conjugates (ADCs) and how many of them are available in the market?
• What are the common cytotoxic “warheads” used in ADCs?
• What are the important clinical assets in ADCs?
• How many bispecific MAbs are in late-stage development?
• What are the common side effects of MAbs in cancer immunotherapy?
• What are cancer vaccines and how many of them have been licensed to be marketed?
• How many cytokines have been approved for being used in cancer immunotherapy?
• What are the major checkpoint inhibitors in clinical development?
• What is the current status of anti-PD-1 drugs, dentritic cell therapies, T-cell therapies and cancer vaccines?
• What are the most valuable R&D projects in cancer immunotherapy and what would be their approximate sales revenues in 2020?
• Number of melanoma drugs approved between 1998 and 2014?
• Number of lung cancer drugs approved between 1998 and 2014?
• Number of brain cancer drugs approved between 1998 and 2014?
• What is the global market for cancer immunotherapeutics by geography, through 2020?
• What is the global market for cancer immunotherapeutics by product class such as MAbs, vaccines and non-specific immunotherapies, through 2020?
• What is the global market for cancer immunotherapeutics by indication, through 2020?
• What is the global market for MAbs by type such as naked MAbs and ADCs, through 2020?
• What are the market values for Herceptin, Avastin, Erbitux, Yervoy, Mabthera, Adectris, and Keytruda?
• What is the global market for cancer vaccines?
• What is the global market for cytokines in cancer immunotherapy?
• The projected market values for Nivolumab, RG7446, DCVax-L, MEDI4736 etc.?

Report Link: http://mrr.cm/4YZ

Find all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics

Human Growth Hormone market in the US to grow at a CAGR of 3.86% over the period 2014-2019, Finds New Report

Report forecast the Human Growth Hormone market in the US to grow at a CAGR of 3.86 percent over the period 2014-2019.

Human growth hormone, also known as somatotropin, is a peptide with 191 amino acids and 2 sulfhydryl bridges. It is produced by the anterior pituitary, and it is required to attain normal size for children and adolescents. It also has major effects on lipid and carbohydrate metabolism of an individual. The effects of human growth hormone are mainly mediated by IGF-1 and IGF-2. There are two forms of recombinant human growth hormone approved in the market: Somatropin and Somatrem. Somatropin has 191 amino acids and Somatrem contains 192 amino acids. Growth hormone deficiency can occur either due to a damage to the pituitary or the hypothalamus gland, or can also be acquired genetically. Some of the signs of growth hormone deficiency are adiposity, short stature, and hypoglycemia.

This report covers the present scenario and the growth prospects of the Human Growth Hormone market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the various human growth hormone drugs available in the US for the treatment of growth hormone deficiency.

According to the report, human growth hormone is administered to patients with various complications such as growth hormone deficiency, Noonan and Turner syndromes, and infants who are born small for their gestational age. High incidence and prevalence of these diseases result in increased demand for human growth hormone

Further, the report states that all of the approved drugs available in the market are biologics. The development process of these biologics is expensive, thereby leading to increased pricing of these drugs. These biologics need to be kept in cold storage to retain their efficacy and avoid local reactions. Therefore, special machinery and care are required to ensure the supply of potent growth hormones.

The Human Growth Hormone Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Human Growth Hormone market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

key players in the Human Growth Hormone Market in the US: F. Hoffmann-La Roche Ltd., Merck Serono SA, Novo Nordisk A/S and Pfizer Inc.

Other Prominent Vendors in the market are: Eli Lilly, Ipsen, Novartis and Teva Pharmaceutical.

Market Driver

• Demand for Human Growth Hormone
• For a full, detailed list, view our report

Market Challenge

• High Cost of Therapy
• For a full, detailed list, view our report

Market Trend

• Growing Focus on Needle-free Drug Delivery Devices
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 84 pages “Human Growth Hormone Market in the US 2015-2019” report covers the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Human Growth Hormone: An Overview, Market Landscape, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis.

For further information on this report, please visit- http://mrr.cm/4fK

Browse more Healthcare reports at:

http://www.marketresearchreports.com/healthcare

Global Middle East and Africa Solid Organ Transplant Immunosuppressant Industry Market 2015, Finds New Report

2015 Market Research Report on Global Middle East and Africa Solid Organ Transplant Immunosuppressant Industry is a professional and deep research report in this field.

For overview analysis, the report introduces Middle East and Africa Solid Organ Transplant Immunosuppressant basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.

For international and China market analysis, the report analyzes Middle East and Africa Solid Organ Transplant Immunosuppressant markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different types and applications, developments and trends of market, technology, competitive landscape, and leading suppliers’ and countries’ 2009-2014 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as products, customers, application, capacity, market position, and company Contact information, etc. 2015-2020 forecast on capacity, production, cost, price, profit, production value, and gross margin for these markets are also included.

For technical data and manufacturing plants analysis, the report analyzes Middle East and Africa Solid Organ Transplant Immunosuppressant leading suppliers on capacity, commercial production date, manufacturing plants distribution, R&D status, technology sources, and raw materials sources.

For industry chain analysis, the report covers Middle East and Africa Solid Organ Transplant Immunosuppressant upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals, which more specifically include valuable information on Middle East and Africa Solid Organ Transplant Immunosuppressant key applications and consumption, key regions and consumption, key global distributors , major raw materials suppliers and contact information, major manufacturing equipment suppliers and contact information, major suppliers and contact Information, key consumers and contact information, and supply chain relationship analysis.

This report also presents Middle East and Africa Solid Organ Transplant Immunosuppressant product specification, manufacturing process, and product cost structure etc. Production is separated by regions, technology and applications. In the end, the report includes Middle East and Africa Solid Organ Transplant Immunosuppressant new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis.

In conclusion, it is a deep research report on global Middle East and Africa Solid Organ Transplant Immunosuppressant industry. Here, we express our thanks for the support and assistance from Middle East and Africa Solid Organ Transplant Immunosuppressant industry chain related technical experts and marketing engineers during research team’s survey and interviews.

Spanning over 179 pages “2015 Market Research Report on Global Middle East and Africa Solid Organ Transplant Immunosuppressant Industry” report covers the Middle East and Africa Solid Organ Transplant Immunosuppressant Industry Overview, Middle East and Africa Solid Organ Transplant Immunosuppressant International and China Market Analysis, Middle East and Africa Solid Organ Transplant Immunosuppressant Technical Data and Manufacturing, Middle East and Africa Solid Organ Transplant Immunosuppressant Production by Regions By Technology, Middle East and Africa Solid Organ Transplant Immunosuppressant Manufacturing Process and Cost Structure, 2009-2014 Middle East and Africa Solid Organ Transplant Immunosuppressant Productions Supply Sales Demand Market Status and Forecast, Middle East and Africa Solid Organ Transplant Immunosuppressant Key Manufacturers Analysis, Up and Down Stream Industry Analysis, Middle East and Africa Solid Organ Transplant Immunosuppressant Marketing Channels Analysis, 2015-2020 Middle East and Africa Solid Organ Transplant Immunosuppressant Industry Development Trend, Middle East and Africa Solid Organ Transplant Immunosuppressant Supply Chain Relationship Analysis, Middle East and Africa Solid Organ Transplant Immunosuppressant New Project Investment Feasibility Analysis, Global Middle East and Africa Solid Organ Transplant Immunosuppressant Industry Research Conclusions.

For further information on this report, please visit- http://mrr.cm/4fF

Browse more Medical Tourism reports at: http://www.marketresearchreports.com/medical-tourism

US Pharmaceutical Market Value Will Approach $550 Billion by 2020; Finds New Report

The US pharmaceutical market is forecast to increase from an estimated value of $395.2 billion in 2014 to reach $548.4 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.6%, according to new report.

The company’s latest report* states that this growth will be driven by a number of factors, including increasing healthcare expenditure, an aging population, the rising prevalence of chronic lifestyle diseases such as diabetes and obesity, universal and easy access to reimbursement for pharmaceutical product costs, and the 2010 Patient Protection and Affordable Care Act (PPACA).

Publisher’s Director of Healthcare Industry Dynamics, explains that the PPACA and its amendment, the Health Care and Education Reconciliation Act, continue to have a substantial impact on US citizens and the country’s pharmaceutical industry.

Publisher’s Director says: “As the PPACA mandates health insurance coverage for all Americans, the US has witnessed increasing use of prescription drugs among individuals who are newly insured or have shifted to insurance plans that offer premium and cost-sharing subsidies. In 2014, spending on prescription drugs amounted to an estimated $275.9 billion, compared with $262.3 billion in 2013.

“Around 20 provisions of the healthcare legislation are expected to have a direct or indirect impact on the volume of drug and biologic sales. As many as 32 million formerly uninsured citizens could enter the patient pool, resulting in new business worth $115 billion over a period of 10 years.”

Publisher’s report also notes that the US Food and Drug Administration (FDA) provides a transparent, well-structured and competent regulatory system to facilitate the approval of pharmaceutical products and consequently bolster market growth.

Publisher’s Director continues: “New initiatives undertaken by the FDA to strengthen the review and approval process will be advantageous to the industry. Its strong patent system attracts research-based pharmaceutical companies and positively influences growth.

In 2014, 41 novel drugs were approved by the FDA, 17 of which were for the treatment of rare diseases. Schemes such as the FDA’s Fast Track Development Program and Breakthrough Designation accelerate the approval of novel drugs and add value to the market by meeting demand more quickly.

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - US report provides information on the healthcare, regulatory, and reimbursement landscape in the US. It includes an overview of the pharmaceutical and medical device sectors, including market size, segmentation, and key drivers and barriers, as well as annualized revenue data from 2013 and forecast to 2020.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For further information on this report, please visit- http://mrr.cm/4fL

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Spain’s Pharmaceutical Market Declining While Medical Devices Sector Grows by 2020; Finds New Report

Austerity measures implemented by the Spanish government have negated the effect of key drivers behind the country’s pharmaceutical market, resulting in a contracting market between 2008 and 2020, according to new report.

However, the company’s latest report states that factors, such as an aging population and free healthcare service, will help drive an overall expansion of the country’s healthcare market over the next six years.

According to Publisher, Spain’s medical devices space was worth approximately $7.1 billion in 2008 and increased to around $8.5 billion in 2013, at a Compound Annual Growth Rate (CAGR) of 3.4%. It is expected to reach $12 billion by 2020, representing a CAGR of 5%.

The in vitro diagnostics and diabetic care device segments were the largest contributors to Spain’s medical device market in 2013. Other major segments included orthopedic, cardiovascular and ophthalmic devices.

Publisher’s Director of Healthcare Industry Dynamics, says: “Spain’s medical devices sector is benefiting significantly from the increase in electronic health services and a strong MedTech industry. However, new drug pricing policies and the promotion of generics as a cost-containment tool are severely limiting the country’s pharmaceutical market growth.

“The government’s new policies, introduced in 2011 and 2012, require drug manufacturers to price their products lower than the reference price, and it is now mandatory for pharmacists to dispense the cheapest available drugs to patients, further impacting pharmaceutical market value.”

Publisher states that due to these strict regulations to contain costs by 2020, the Association Européenne des Spécialités Pharmaceutiques Grand Public (AESGP) reported a decline in Spain’s pharmaceutical market revenues, from $29 billion in 2008 to $24 billion in 2013, at a negative CAGR of 3.7%.

The market’s value is expected to decrease even further to $22.6 billion by the end of the forecast period, representing a negative CAGR of 0.9%.

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Spain report provides information on the healthcare, regulatory, and reimbursement landscape in Spain. It includes an overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers, as well as an evaluation of the opportunities for and challenges to growth.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For further information on this report, please visit- http://mrr.cm/4f2

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Japanese Pharmaceutical Market Value Edging Towards $80 Billion by 2020; Finds New Report

Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country’s aging population, according to new report.

However, the company’s latest report* states that the Japanese government’s promotion of generic drugs, its biennial pricing review system and the depreciation of the yen against the dollar will be limiting factors in what is the second largest mature pharmaceutical market in the world by value.

The market was valued at $64.2 billion in 2008 and peaked at $88 billion in 2011, before a slight dip to $87.2 billion in 2012. A substantial drop in 2013 saw its value decrease by over $14 billion, but Publisher expects a steady period of recovery to follow.

Publisher’s Director of Healthcare Industry Dynamics, says: “Deregulation measures introduced in April 2005 have had an impact on overall market performance and more efficient drug reviews have facilitated the entry of new products.

“The approval process has now caught up with that outside of Japan, as highlighted by two approvals for Bristol-Myers Squibb, the Daklinza (daclatasvir) and Sunvepra (asunaprevir) dual regimen for hepatitis C, and Opdivo (nivolumab) for melanoma, prior to their approval by the US Food and Drug Administration.”

Aside from wider economic factors, such as currency exchange rates, Publisher states that increased use of generic drugs will be a key contributor to the forthcoming period of slow growth to 2020.

Publisher’s Director continues: “In 2008, generics accounted for 19% of the pharmaceutical space in terms of volume, rising to 25.2% in 2013. Japan has set a goal for generics to account for 60% of all drug use by 2017.

To this end, the Ministry of Health, Labor and Welfare announced new price cuts in 2013 for drugs with generic replacement of less than 60%, a move which is likely to limit future growth in the pharmaceutical arena.

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan report provides information on the healthcare, regulatory, and reimbursement landscape in Japan. It includes annualized data on the pharmaceutical and medical device sectors from 2013 and forecast to 2020, plus an analysis of key market drivers and barriers.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For further information on this report, please visit- http://mrr.cm/4f6

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Global patient monitoring devices market is expected to reach $24,353 million by 2020; Finds New Report

Patient monitoring market is mounting as a result of advancement in upcoming technologies that is providing an excellent opportunity for cultivating improvised care for patients across every corner of the globe. Patient monitoring system involves continuous/semi-continuous measurement of patient’s physiological parameters such as heart rate, respiratory rate, blood pressure, core temperatures and pulse oximetry etc., which accelerates patient’s quality care by making superior clinical-decision. Patient monitoring plays a fundamental role in emergency and operating rooms, intensive and critical care units by reducing onset of complications and risks in patient. It is proven to be very useful in respiratory therapy, recovery rooms, out-patient care, transport, radiology, cath labs, gastroenterology departments, ambulatory, home, and sleep screening applications. 

Patient monitoring devices market is mainly divided into following segments such as by-devices, by-end-users. Patient Monitoring market by-devices are classified into cardiac monitors, fetal, prenatal and neonatal monitors, hemodynamic monitors, multi-parameter monitors, neurological monitors, respiratory monitors, remote patient monitors, micro electromechanical systems-based monitors, temperature and weight monitors. PM market by-end-users are divided into medical centers and medical specialist, primary healthcare and community healthcare centers, laboratories and diagnostic centers and home-based users.

Patient monitoring devices are requisite part of medical team for every procedure i.e. operating in a clinic or multi specialty hospitals. The reduction in size of the monitors over the years through contemporary technologies and rising adoption of telemetry and remote monitoring has increased the growth of the patient monitoring devices. Cardiac monitoring segment commanded the largest share in global patient monitoring market for 2013 and is expected to maintain its strong share by 2019. Multi-parameter monitoring is the second largest share holder in the market. Moreover, respiratory monitoring and neurological monitors is the fastest growing segments due to rising incidence of respiratory and neuro-degenerative diseases and demand for portable devices.

The global patient monitoring devices market is expected to reach approximately $24,353 million by 2020 growing at CAGR of around 5.2%. Geographically, North America commands the largest share and is expected to record a healthy market share by $9,681 million by 2020. APAC is going to be one of the prominent regions for this market in coming years driven by healthcare awareness, high purchasing power and rising population.

Spanning over 334 pages and 45 Tables “Patient Monitoring Global Market – Forecast To 2020” report covers Executive Summary, Introduction, Market Analysis, Global Patient Monitoring System Market, By Device, Global Patient Monitoring System Market, By End-Users, Regional Market Analysis, Company Developments, Major Company Profiles. This Report Covered 10 Companies - Abbott Laboratories, Boston Scientific Corporation, Covidien, Ge Healthcare, Johnson & Johnson, Medtronic, Omran Healthcare, Philips Healthcare, Roche Diagnostics, St. Jude Medical, Inc.

For further information on this report, please visit- http://mrr.cm/4fQ

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Global Next Generation Sequencing market is expected to reach $4,892 million by 2020; Finds New Report

A decade has gone, since the first human genome has been sequenced and sequencing technology has come a long way from the time of introduction as Next generation Sequencing (NGS) has revolutionized the way the human genomes are being sequenced now a days. The time and cost to sequence has tremendously reduced since the first human genome was sequenced, which took a decade time and around $3 billion. According to experts, in the coming years, a human genome can be sequenced at a cost of $1,000 in one to two days. In the last five years the sequencing cost has rapidly reduced and this is supposed to have a huge impact on the NGS market in the coming years.

The global Next Generation Sequencing market is valued to be XX million in 2013 and poised to grow at a CAGR of XX% to reach $4,892 million by 2020. The NGS market is classified based on products, technology, end users, application and geography. The global NGS products are further divided into instruments and consumables, services and workflow products. The NGS technology is segmented into targeted resequencing, whole exome sequencing, RNA sequencing, whole genome sequencing, ChIP sequencing, de novo sequencing and methyl sequencing. The NGS market by end users is divided into academic research laboratories, hospitals and clinics, biotech and pharmaceuticals and other end users, which include nonprofit organizations and commercial labs.

The application of NGS market is classified into clinical and non-clinical applications. By application type, the market is broken down into oncology, genetic screening, infectious diseases, drug and biomarker discovery, molecular epidemiology, agriculture and animal research and other applications. Further, the NGS market is separated by geographical regions into North America, Europe, Asia-pacific and Rest of the World.

Spanning over 304 pages “Next Generation Sequencing (NGS) Global market - Forecast to 2020” report covers Executive Summary, Introduction, Market Analysis, Next Generation Sequencing Market, By Products, Next Generation Sequencing Market Value And Volume Analysis, By Technology, Next Generation Sequencing Market, By End Users/Laboratories, Next Generation Sequencing Market Value And Volume Analysis, By   Application Area, Geographic Analysis, Company Developments, Major Player Profiles. This Report Covered 10 Companies - Agiltent Technologies Inc, Bgi (Beijing Genomics Institute), Biomatters Ltd, Genomatix Software Gmbh, Illumina, Inc., Pacific Biosciences Of California, Inc., Qiagen.N.V, Hoffmann-La Roche Ltd, Strand Life Sciences Pvt. Ltd., Thermo Fishers Scientific, Inc.

For further information on this report, please visit- http://mrr.cm/4fW

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology

Global endoscopy market is expected to reach $47 billion by 2020; Finds New Report

Endoscopy is a minimal invasive procedure to view the internal organs of the body. Endoscopic procedures are used to retrieve samples for biopsies, to remove foreign objects inside the body and to perform keyhole surgeries. The global endoscopy market is classified by product and application types. Rigid, flexible, capsule and video endoscopes are the major types of endoscope products. Depending on the medical applications the market is segmented into arthroscopy, colonoscopy, laparoscopy, gastro intestinal endoscopy, bronchoscopy, Urology endoscopy, and gynecology endoscopy.

The global endoscopy market is expected to reach approximately $47 billion by 2020 growing at around 7.0% CAGR from 2014 to 2020. The major drivers for the market growth are aging population, increase in cancer, diabetes, and obesity patients along with a rise in patient’s preference for minimal invasive surgeries. Additionally, shorter stay in hospitals, speedy recovery, and reduced medical budget enhance the growth of the market. However, the shortage of qualified endoscopic technicians, high cost of initial investment, contamination risk and patient safety of endoscopic procedures pose a threat for the market growth.

Advancement in the field of endoscopic devices with accurate visibility, high definition imaging and documentation, ease of handling and cleaning the devices and growing demand in emerging countries brings in more opportunities for the endoscopy market.

The global endoscopy devices products market is segmented into endoscopes, visualization and documentation systems, endoscopic accessories and services. The endoscopes segment commanded the largest market in 2013 and is expected to grow strong by 2020. The visualization and documentation system is expected to grow at the highest CAGR of nearly 10.0% during the forecast period. Among the applications segment Laparoscopic application segment holds the largest market in 2013 and Neurology application segment is expected to grow at the highest CAGR of more than 10% during the forecast period.

North America accounts for the largest market share with increase in endoscopic treatment options and obese population followed by Europe and Japan. Although U.S. has a high market share, there is a growing demand for endoscopy market in the emerging countries such as India and China. Along with an increase in medical spending, improvement in medical infrastructure and changes in life style attribute to the growth of the market in emerging countries.

Spanning over 346 pages and 18 Tables “Endoscopy Global Market – Forecast to 2020” report covers Executive Summary, Introduction, Market Analysis, Endoscopy Devices Global Market, By Application, Endoscopy Market, By Products, Regional Market Analysis, Company Developments, Major Player Profiles. This Report Covered 10 Companies - Boston Scientific Corporation, Conmed Corporation, Covidien Plc, Ethicon Endosurgery, Inc., Fujifilm Holdings Corporation, Hoya Corporation, Karl Storz Gmbh & Co. Kg, Olympus Corporation, Smith & Nephew Plc, Tryker Corporation.

For further information on this report, please visit- http://mrr.cm/4fd

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Global diagnostic imaging market is expected to reach $33,188 million by 2020; Finds New Report

Diagnostic imaging is being identified as one of the matured markets among the healthcare sector. Advances in diagnostic imaging technology have redefined how physicians diagnose and treat some of the most life threatening diseases such as cancer and heart disease and they have nearly eliminated the need for exploratory surgery. Imaging techniques would be therefore enabling us to diagnose, treat and cure patients without causing any harmful side effects. The different diagnostic imaging modalities include X-ray systems, Computed Tomography (CT) Scanners, Magnetic Resonance Imaging (MRI) systems, Ultrasound systems and Nuclear imaging systems. The global diagnostic imaging market is valued at $23,282 million in 2013 and is expected to grow at a CAGR of 5.1% to reach $33,188 million by 2020.

There are many factors involved in driving the growth of the diagnostic imaging market such as emerging applications in diagnostic procedures, high prevalence of the diseases, ongoing research activities all over the world and most important thing, awareness in people about the use of early disease diagnosis. On the other hand the high cost of the diagnostic imaging systems, risk of the radiation exposure, shortage of helium for MRI systems, poor healthcare insurance coverage particularly for the diagnostic procedures are restricting the market growth.

North America holds the largest share in the global diagnostic imaging market, followed by Europe. However, the Asia-Pacific market is expected to grow at the fastest CAGR in the coming five years. The Asian and Latin American countries represent the fastest growing markets due to increasing government support for research and rising industry and academic partnerships for research activities. But still the factors like economic slowdown, pricing pressures may compel the companies to focus on Asian markets.

Spanning over 363 pages and 12 Tables “Diagnostic Imaging Global Market – Forecast To 2020” report covers Executive Summary, Introduction, Market Analysis, Diagnostic Imaging Technologies Global Market, By Products, Global Diagnostic Imaging Market, Technology Outlook, Diagnostic Imaging Technologies Global Market, Applications Outlook, Diagnostic Imaging Technologies Global Market,  By End-Users, Regional Market Analysis, Introduction, Major Player Profiles. This Report Covered 8 Companies - Ge Healthcare, Hitachi Medical Corporation, Inc., Hologic, Inc., Philips Healthcare, Samsung Medison, Shimadzu Corporation, Siemens Healthcare, Toshiba Medical Systems Corporation.

For further information on this report, please visit- http://mrr.cm/4fA

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Global active pharmaceutical ingredient market is expected to reach $175 billion by 2020; Finds New Report

The global active pharmaceutical ingredient market is expected to reach approximately $175 billion by 2020, growing at a CAGR of around 6% during forecast period. Active pharmaceutical ingredient is any substance or mixture of substances used in a finished pharmaceutical product with pharmacological activity used for diagnosis, cure, mitigation, treatment and prevention of diseases. Very less number of finished pharmaceutical product manufacturers has their own API manufacturing unit and nobody can make all required APIs in-house. It is basically not easy for API manufacturers in developing countries to ensure a product with quality at a reasonable price. API manufacturing involves conversion of raw materials into API and mixing API and excipients for final formulations. These formulations in the form of tablets, capsules or solutions are packaged and then marketed.   

Patent expiration of major drugs that increased generic drug sales, government initiatives, increasing aged population and regional penetration, local manufacturer expansion and high uptake of biologics are some of the factors that are driving the market growth. Whereas financial crisis, stringent regulatory policies, less investment in pharmaceutical industry and fragmented market are the factors that are hindering API market growth.

The global API market is segmented based on synthesis, customer base, business type and therapeutic applications. Depending on synthesis the market is classified into synthetic chemical API, biotech API and HPAPI (Highly Potent Active Pharmaceutical Ingredient). Biotech API is further segmented into mammalian cell culture, monoclonal antibodies, recombinant proteins, vaccines, insulin analog, growth hormones and interferons. Mammalian cell culture accounted for the largest share in 2013, while monoclonal antibody segment is the fastest growing segment by 2020. Despite low production yields, high manufacturing cost and highly unstable cell culturing method mammalian culture is the largest due to post-translational mechanism present in living cells. Monoclonal antibodies are growing at a faster pace due to demand for biotech APIs and increasing venture capital investments that drives the market.

By-customer base the API market is segmented into synthetic chemicals API, biotech API and HPAPI. Synthetic chemical API is further classified into branded/innovative and generic/non-branded API. Branded API accounted for the largest share whereas, generic is the fastest growing segment. Biotech API is further divided into biologics and biosimilars where biologics accounted for the largest share.

Depending on business type the API market is segmented into captive and merchant. Captive market accounted for the largest revenue in 2013.  Based on the therapeutic applications the global API market is categorized into eleven crucial application areas such as anti-infectives, oncology, cardiovascular and hematopoietic system, central nervous system, gastrointestinal disorder, respiratory system, hormonal-related disorder, metabolic disorder, genito-urinary disorder, musculo-skeletal disorder and others. Anti-infectives segment dominated the application market with a largest in 2013 whereas oncology segment is the fastest growing segment with a CAGR of approximately 8% by 2020. Patent expiration of major drugs, increased incidence of various cancer diseases and aged population, high government investments for cancer research and healthcare awareness are the factors that drives the market whereas stringent regulations, failure of crucial drugs in last stage of clinical trial, and economical crisis are the factors that hampers the market growth.

Geographically API market is segmented into North America, Asia-Pacific, Europe and Rest of the world regions. North America dominated the global API market during the forecast period. Asia Pacific region is the fastest growing with a CAGR of more than 7.5% by 2020 due to patent expirations of drugs, low operation costs, services of Contract Manufacturing Organizations (CMO) and high investments in medical research. Moreover the high cost of skilled labor and energy are the major factors that forced European market to shift their base to countries such as India and China.   

Major players in the API market include Teva Active Pharmaceutical Industries Limited (Israel), Ranbaxy Laboratories (India), Dr. Reddy's Lab (India), Boehringer Ingelheim GmbH (Germany), Lonza group (Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo pharma (India), and Albemarle Corporation (U.S.).

Spanning over 282 pages and 51 Tables “Active Pharmaceutical Ingredients Global Market – Forecast to 2020” report covers Executive Summary, Introduction, Market Analysis, Global Api Market Overview, Global Api  Market, By Therapeutic  Application, Regional Market Analysis, Company Developments, Major Player Profiles. This Report Covered 11 Companies - Teva Active Pharmaceutical Industries Limited (Israel), Ranbaxy Laboratories (India), Dr. Reddy's Lab (India), Boehringer Ingelheim Gmbh (Germany), Lonza Group (Switzerland), Lupin (India), Novartis (Switzerland), Aurobindo Pharma (India), Albemarle Corporation (U.S.), Sun Pharmaceuticals (India), Fresenius Kabi (Germany).

For further information on this report, please visit- http://mrr.cm/4fP

Find all Pharmaceutical Manufacturing Reports at: http://www.marketresearchreports.com/pharmaceutical-manufacturing

Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015; New Report Launched

Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Billions of dollars are spent on the chemotherapy treatments annually. Different Biotechnology companies and Pharma Companies are collaborating in all area of ADCs like linker technology, antibody production and conjugation process. Seattle Genetics’s Brentuximab vedotin and Roche’s trastuzumab emtansine are the only ADCs approved which have together made USD 523 millions sales in 2013. There are total 264 ADCs in pipeline with 253 ADCS are developing only for Oncology indications. Pipeline is very rich with four potential drugs in Phase III stage out of which Kadcyla and Adcetris are undergoing clinical studies for different conditions. According to Publisher Analysis, North America has the highest number of development in ADCs with 161 ADCs and 65 Active companies followed by Europe with 38 active companies and 81 products and Asia Pacific with 18 ADCs in development.

Scope

• A snapshot of the global Antibody-Drug Conjugate market scenario, market trends & drivers, manacles of Antibody-Drug Conjugate.
• A review of the marketed Antibody-Drug Conjugate products and marketing status
• Coverage of global antibody-drug conjugate therapies under development across the globe covering territories
• Competitive landscape of investigational products for key players and key therapy areas.
• The Antibody-Drug Conjugate report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information
• The Report also provides the pre-clinical and clinical outcomes of the therapies
• The Report has covered the targets and detailed mechanism of action
• Report has highlighted the licensing opportunities and funding details for therapies
• The report also gives the information of dormant and discontinued pipeline projects

Reason to Buy

• Complete Market and Pipeline intelligence and complete understanding over therapeutics development for Antibody-Drug Conjugate
• Devise corrective measures for pipeline projects by understanding Therapy area specific therapies
• Developing strategic initiatives to support your Antibody-Drug Conjugate development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Evaluate the marketing and pipeline strategy for antibody-drug conjugate therapies and their funding details.
• Identifying the upcoming leaders in the Antibody-Drug Conjugate market in the coming years.

Spanning over 342 pages, 15 Tables and 17 Figures “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015” report covers Introduction, Executive Summary, Scope of the Report, Antibody-Drug Conjugate Introduction, Global Sales Assessment of Adcetris, Market Size Assessment of Antibody-Drug Conjugates, Report Methodology.

For further information on this report, please visit- http://mrr.cm/4fY

Find all Pharmacy Reports at: http://www.marketresearchreports.com/pharmacy

In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2020; New Report Launched

In vitro diagnostics are tests that diagnose and prevent diseases, conditions or infections. IVD tests are performed outside body in an artificial environment on samples such as blood, urine, tissue isolated from human body. IVD is classified into 3 types namely: clinical laboratory testing, near-patient testing, self-testing. IVD market is segmented by-techniques (including immunoassays, point of care, molecular diagnostics, hematology, coagulation, microbiology, clinical techniques, microbiology), product-type (including instruments, reagents, services, data management systems), usability (including disposable, reusable), applications (including diabetes, oncology, cardiology, HIV/AIDS, autoimmune disease, nephrology, drug testing), -end-user (including hospitals, laboratories, academics) and geography (globally). 

The global IVD market was reported with high revenue in previous years and hence expected to grow at a high CAGR by 2019. The Asia-Pacific and RoW regions are expected to register a significant growth rate for the IVD market. North America commands the largest share while Asia Pacific is the fastest revenue growing region.

IVD market growth is driven by factors such as increase in incidences of chronic and infectious diseases across all age cohorts, genetic diseases, aging population, rising acceptance of personalized medicine, rise in healthcare awareness in patients and high unmet medical needs in diagnosing diseases. Screening initiatives and high investment in healthcare infrastructures mainly contributes to market growth. Whereas, difficulty in rendering rapid diagnostic results, stringent regulatory policies, reimbursement issues and economic crisis are the major growth restraints. Different geographies is an opportunistic factor which improved IVD market growth.

Roche diagnostics (Basel, Switzerland) is expected to be the largest player in the IVD market, followed by Siemens and Abbott. The IVD market is highly consolidated, with the major players holding close to 80% market share. Top ten major players are Roche Diagnostics, Siemens Healthcare(Erlangen, Germany), Abbott(Abbott Park, Illinois), Johnson and Johnson(New Jersey), Beckman Coulter(Massachusetts), Becton Dickinson(U.S.), bioMerieux (France), Bayer Diabetes(Germany), Sysmex (U.S.) and Bio-Rad(California). Key players such as Thermo Fisher Scientific, Inc., QIAGEN N.V., and ARKRAY, Inc. have established new manufacturing facilities and R&D units in China to grow IVD market.

The focus of this research report description was on various levels of analysis, industry, market shares, value chain, PESTEL analysis and company profiles which together comprise and augment about competitive landscape, emerging and high growth segments of in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Spanning over 239 pages “In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2020” report covers the Executive Summary, Introduction, Market Analysis, Global Ivd Market, By Technique, Global Ivd Market, By Products, Global Ivd Market, By Application, Global Ivd Market, By End-Users, Regional Market Analysis, Company Developments, Major Player Profiles. The report covered companies are - Abbott Laboratories, Inc., Becton, Dickinson and company, Biomerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, Johnson and Johnson, Roche Diagnostics, Siemens Healthcare, Sysmex Corporation, Thermo Fischer Scientific, Inc.

For further information on this report, please visit- http://mrr.cm/4fT

Find all Pharma and Healthcare Technology Reports at:

http://www.marketresearchreports.com/pharma-healthcare-technology